Study finds no cardiovascular risk difference between JAK and TNF inhibitors in IBD patients

A new study found that patients with inflammatory bowel disease (IBD) using Janus kinase (JAK) inhibitors have a similar risk of major cardiovascular events compared to those using tumor necrosis factor (TNF) inhibitors. The study reported rates of 3.10% for JAK inhibitors and 4.27% for TNF inhibitors. This research contrasts with earlier findings that indicated higher cardiovascular risks for rheumatoid arthritis patients on JAK inhibitors. The study did not find significant differences in individual cardiac events or secondary outcomes like all-cause mortality and malignancy between the two groups. The analysis included over 10,000 patients and adjusted for various factors, including demographics and previous medications. Researchers hope these findings will encourage further studies on the long-term safety of JAK inhibitors in IBD patients.